Latest Recruitment News

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Amplia Therapeutics has launched a Phase 2b trial testing a new daily dosing regimen of narmafotinib combined with chemotherapy in advanced pancreatic cancer, aiming to accelerate progress towards a pivotal Phase 3 study.

Abacus Group (ASX:ABG) is set to internalise management of Abacus Storage King (ASK), acquiring full control of ASK’s responsible entity for $24 million. The move marks a strategic shift as ABG refocuses on its core commercial real estate business.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

Dataworks has officially launched BetGuard, iGaming Ontario's Centralised Self-Exclusion tool, alongside a dedicated Contact Centre, marking its expansion into a second regulated jurisdiction for responsible gambling technology.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Bapcor reports a turnaround in sales momentum after February 2026 but lowers its full-year earnings forecast due to geopolitical and cost pressures.

Maronan Metals is set for a leadership change as Managing Director Richard Carlton steps down in December 2026, with a CEO search underway to guide the project through feasibility and mine development.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.

EDU Holdings delivered a transformational FY25 with nearly doubled revenue and a debt-free balance sheet, driven by strong growth in its higher education arm Ikon. The company started FY26 on a solid footing despite regulatory headwinds.

EMVision is broadening its emu™ Pivotal Trial to include acute ischaemia detection, aiming to accelerate FDA clearance and enhance the brain scanner's clinical impact. Recruitment has passed 125 patients across US and Australian sites, with full enrolment expected by early 2027.